NYSEAMERICAN:MAIA MAIA Biotechnology Q3 2026 Earnings Results & Report $1.08 -0.01 (-0.92%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. MAIA Biotechnology beat analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.12 versus the -$0.13 consensus estimate. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeAfter Market ClosesConference Call7:00 AM ET MAIA Biotechnology EPS ResultsActual EPS-$0.12Consensus EPS -$0.13Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersMAIA Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) MAIA Biotechnology Q3 2026 Earnings FAQ Did MAIA Biotechnology beat earnings estimates for Q3 2026? MAIA Biotechnology (NYSEAMERICAN:MAIA) reported earnings of -$0.12 per share for Q3 2026, beating the consensus estimate of -$0.13. The report was announced on Monday, November 9, 2026. MAIA Biotechnology Earnings HeadlinesMAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10 at 6:41 AM | marketscreener.comMMAIA Biotechnology (MAIA) Expected to Release Quarterly Earnings on FridayOctober 30, 2026 | americanbankingnews.comThe Withdrawal You'll Never See on Your StatementA proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.November 10 at 1:00 AM | Bishop Gold Group (Ad)MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%October 7, 2026 | rttnews.comMAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerOctober 7, 2026 | globenewswire.comDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)October 1, 2026 | globenewswire.comSee More MAIA Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email. Email Address About MAIA BiotechnologyMAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells. MAIA’s lead investigational product is THIO, also known as 6-thio-2'-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program. MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D. As a clinical-stage company, MAIA’s products remain investigational and are subject to clinical testing and regulatory review before they can be broadly marketed.View MAIA Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
